28-Mar-2024
No headlines found.
PharmaVentures acts as the exclusive M&A advisor on the successful sale of Phasefocus to Bruker
PRNewswire (Tue, 19-Mar 5:00 AM ET)
Business Wire (Mon, 11-Mar 7:00 AM ET)
Bruker Announces Closing of Chemspeed Technologies AG Acquisition
Business Wire (Thu, 7-Mar 7:00 AM ET)
Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup
Business Wire (Wed, 28-Feb 7:00 AM ET)
Bruker Corporation to Present at Upcoming Investor Conferences
Business Wire (Mon, 26-Feb 10:42 AM ET)
Bruker Announces Quarterly Dividend
Business Wire (Fri, 16-Feb 4:05 PM ET)
Bruker Reports Fourth Quarter and Full Year 2023 Financial Results
Business Wire (Tue, 13-Feb 7:00 AM ET)
Business Wire (Wed, 7-Feb 7:00 AM ET)
Business Wire (Tue, 6-Feb 4:05 PM ET)
Bruker Announces Date and Time of Fourth Quarter 2023 Earnings Release and Webcast
Business Wire (Tue, 6-Feb 7:00 AM ET)
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
Bruker trades on the NASDAQ stock market under the symbol BRKR.
As of March 28, 2024, BRKR stock price climbed to $93.94 with 372,467 million shares trading.
BRKR has a beta of 1.28, meaning it tends to be more sensitive to market movements. BRKR has a correlation of 0.22 to the broad based SPY ETF.
BRKR has a market cap of $13.00 billion. This is considered a Large Cap stock.
Last quarter Bruker reported $854 million in Revenue and $.70 earnings per share. This beat revenue expectation by $47 million and exceeded earnings estimates by $.02.
In the last 3 years, BRKR stock traded as high as $94.86 and as low as $48.42.
The top ETF exchange traded funds that BRKR belongs to (by Net Assets): IJH, VTI, VB, VXF, VBK.
BRKR has underperformed the market in the last year with a price return of +23.2% while the SPY ETF gained +33.6%. However, in the short term, BRKR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +27.7% vs +10.1% return in SPY. But in the last 2 weeks, BRKR shares have been beat by the market, returning +1.4% compared to an SPY return of +1.7%.
BRKR support price is $92.50 and resistance is $95.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BRKR stock will trade within this expected range on the day.